Jpmorgan Chase & CO Century Therapeutics, Inc. Transaction History
Jpmorgan Chase & CO
- $1.27 Trillion
- Q1 2025
A detailed history of Jpmorgan Chase & CO transactions in Century Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 69,490 shares of IPSC stock, worth $38,219. This represents 0.0% of its overall portfolio holdings.
Number of Shares
69,490
Previous 163,189
57.42%
Holding current value
$38,219
Previous $164,000
79.88%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding IPSC
# of Institutions
66Shares Held
23.8MCall Options Held
33.4KPut Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA5.41MShares$2.98 Million0.91% of portfolio
-
Black Rock Inc. New York, NY2.9MShares$1.59 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.11MShares$1.16 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.02MShares$1.11 Million0.0% of portfolio
-
Dafna Capital Management LLC Los Angeles, CA1.7MShares$937,3270.28% of portfolio
About Century Therapeutics, Inc.
- Ticker IPSC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,881,800
- Market Cap $32.4M
- Description
- Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...